Investing.com -- The U.S. Food and Drug Administration has appointed Katherine Szarama as acting director of its Center for Biologics Evaluation and Research, Politico reported on Thursday.
Szarama takes over the unit following the departure of Vinay Prasad, whose time at the agency ended this week. The center oversees vaccines, gene therapies and the blood supply.
FDA Commissioner Marty Makary said earlier this week that no permanent successor to Prasad had been selected and an announcement was expected in the coming weeks.
Prasad, an oncologist, had been a vocal critic of U.S. drug and vaccine policies, particularly regarding COVID-19 mandates, before joining the FDA. His tenure was marked by several high-profile decisions on rare disease drugs and vaccines, according to the report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.